mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

@article{Mabuchi2009mTORIA,
  title={mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.},
  author={Seiji Mabuchi and Chiaki Kawase and Deborah A Altomare and Kenichirou Morishige and Kenjiro Sawada and Masami Hayashi and Masahiko Tsujimoto and Mareo Yamoto and Andres J. P. Klein-Szanto and Russell Schilder and Masahide Ohmichi and Joseph R Testa and Tadashi Kimura},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 17},
  pages={5404-13}
}
PURPOSE Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation and is regarded as a promising target in cancer therapy, including for ovarian cancer. This study aimed to examine the role of mTOR as a therapeutic target in clear cell carcinoma of the ovary, which is regarded as an aggressive, chemoresistant histologic subtype. EXPERIMENTAL DESIGN Using tissue microarrays of 98 primary ovarian cancers (52 clear cell carcinomas and 46 serous adenocarcinomas), the… CONTINUE READING